Zusammenfassung
2-Methoxyestradiol (2-ME2) ist ein physiologischer Östrogenmetabolit, der das Wachstum vieler verschiedener Tumortypen hemmt. Viele Wirkmechanismen sind beschrieben worden. Neben einem starken antiangiogenetischen und proapoptotischen Effekt gibt es weitere wichtige Wirkungen wie die Hemmung der Mikrotubuli während der Mitose und die Hemmung des Hypoxia-Inducible-Factor 1α (HIF-1 α). Multiresistente Tumorzellen auf Zytostatika zeigten sich komplett sensibel gegenüber der Behandlung mit 2-ME2. Studien mit hohen Dosen 2-ME2 ergaben, dass die Nebenwirkungen auf gesunde Zellen und Organe minimal waren. Aufgrund der experimentellen Ergebnisse wurden verschiedene klinische Studien bei Patienten mit verschiedenen Tumoren initiiert. Wir fassen hier die wichtigsten tumorhemmenden Wirkungen von 2-ME2 sowie die Darstellung der aktuellen Studien zusammen.
Summary
2-Methoxyestradiol (2-ME2), a physiological metabolite of estrogen, inhibits the growth of different tumor types. Many mechanisms of action have been described. In addition to a strong antiangiogenic effect and induction of apoptosis, there are other important mechanisms, such as the inhibition of microtubules during mitosis or the inhibition of the hypoxia-inducible-factor 1α (HIF1 α). Multidrug-resistant cancer cells appear to be highly sensitive to 2-ME2. Studies with high dosage 2-ME2 have shown that there are only minimal reversible side effects on normal tissue. The experimental data on human tumors have led to the initiation of several clinical trials with promising results. We here summarize the effect of 2-ME2 on various tumor types in vitro and in vivo, as well as the initial results of current clinical trials.
Literatur
-
1
Chauhan D, Catley L, Hideshima T. et al .
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.
Blood.
2002;
100
2187-2194
-
2
DŽAmato R J, Lin C M, Flynn E, Folkman J, Hamel E.
2- Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site.
Proc Natl Acad Sci.
1994;
91
3964-3968
-
3
Feigelson H S, Henderson B E.
Estrogens and breast cancer.
Carcinogenesis.
1996;
17
2279-2284
-
4
Fotsis T, Zhang Y, Pepper M S. et al .
The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth.
Nature.
1994;
368
237-239
-
5
Han G Z, Liu Z J, Shimoi K, Zhu B T.
Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Cancer Res.
2005;
65
387-393
-
6
Huang P, Feng L, Oldham E A. et al .
Superoxide dismutase as a target for the selective killing of cancer cells.
Nature.
2000;
407
390-395
-
7
Huober J B, Nakamura S, Meyn R. et al .
Oral administration of an estrogen metabolite-induced potentiation of radiation Antitumor effects in presence of wild-type p53 in non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys.
2000;
48
1127-1137
-
8
Kataoka M, Schumacher G, Cristiano R J, Atkinson E N, Roth J A, Mukhopadhyay T.
An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo.
Cancer Res.
1998;
58
4761-4765
-
9
Klauber N, Parangi S, Flynn E. et al .
Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.
Cancer Res.
1997;
57
81-86
-
10
Lakhani N J, Sparreboom A, Venitz J, Dahut W, Figg W D.
Single oral dose pharmacokinetics (PK) and safety of 2-methoxyestradiol (2-ME2) in patients with solid tumors.
Proc Am Ass Clin Oncol.
2005;
2071
-
11
LaVallee T M, Zhan X H, Herbstritt C J. et al .
2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta.
Cancer Res.
2002;
62
3691-3697
-
12
Mack T M, Pike M C, Henderson B E. et al .
Estrogens and endometrial cancer in a retirement community.
N Engl J Med.
1976;
294
1262-1267
-
13
McCormick D L, Johnson W D, Pribluda V S, Green S J, Tomaszewski J E, Smith A C.
Preclinical development of 2-methoxyestradiol (2ME2, NSC-659 853).
Proc Am Assoc Cancer Res.
2000;
41
328
-
14
Miller K D, Murry D J, Curry E. et al .
A phase I study of 2-methoxyestradiol (2ME2) plus docetaxel (D) in patients (pts) with metastatic breast cancer (MBC).
Proc Am Ass Clin Oncol.
2002;
442
-
15
Mukhopadhyay T, Roth J A.
Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol.
Oncogene.
1997;
14
379-384
-
16
Mukhopadhyay T, Roth J A.
Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis.
Oncogene.
1998;
17
241-246
-
17
Reiser F, Way D, Bernas M, Witte M, Witte C.
Inhibition of normal and experimental angiotumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol.
Proc Soc Exp Biol Med.
1998;
219
211-216
-
18
Ricker J L, Chen Z, Yang X P. et al .
2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
Clin Cancer Res.
2004;
10
8665-8673
-
19
Schumacher G, Kataoka M, Roth J A, Mukhopadhyay T.
Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines.
Clin Cancer Res.
1999;
5
493-499
-
20
Schumacher G, Langrehr J M, Baumunk D. et al .
2-Methoxyestradiol has growth inhibitory effect alone and in combination with conventional chemotherapy on human pancreatic cancer cells and inhibits growth of multi-drug resistant pancreatic cancer cells.
Proc Am Assoc Cancer Res.
2003;
44
1304-1305
-
21
Schumacher G, Neuhaus P.
The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors.
J Cancer Res Clin Oncol.
2001;
127
405-410
-
22
Schumacher G, Scheunert S, Nuessler A K. et al .
2-Methoxyestradiol inhibits tumor growth and induces apoptosis in human hepatoma cells.
Proc Am Assoc Cancer Res.
2000;
4909
772-773
-
23
Schumacher G, Scheunert S, Rueggeberg A. et al .
A very low toxic agent induces apoptosis and reduces growth of human hepatocellular carcinoma cells.
J Gastroenterol Hepatol.
2006;
(Im Druck)
-
24
Sledge G W, Miller K D, Haney L G. et al .
A phase I study of 2-methoxyestradiol (2ME2) in patients (pts) with refractory metastatic breast cancer.
Proc Am Ass Clin Oncol.
2002;
441
-
25
Tsutsui T, Tamura Y, Hagiwara M. et al .
Induction of mammalian cell transformation and genotoxicity by 2-methoxyestradiol, an endogenous metabolite of estrogen.
Carcinogenesis.
2000;
21
735-740
-
26
Turner R T, Evans G L.
2-Methoxyestradiol inhibits longitudinal bone growth in normal female rats.
Calcif Tissue Int.
2000;
66
465-469
-
27
Verdier-Pinard P, Wang Z, Mohanakrishnan A K, Cushman M, Hamel E.
A steroid derivative with paclitaxel-like effects on tubulin polymerization.
Mol Pharmacol.
2000;
57
568-575
Priv.-Doz. Dr. med. Guido Schumacher
Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Charité Campus Virchow Klinikum, Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin
Phone: 030/450552313
Fax: 030/450552900
Email: guido.schumacher@charite.de
